EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behçet’s disease

Chiuping Lee, Masaki Takeuchi, Tatsukata Kawagoe, Jutaro Nakamura, Etsuko Shibuya, Mami Ishihara, Norihiro Yamada, Yuki Mizuki, Akira Meguro, Yohei Kirino, Yutaro Soejima, Lisa Hirahara und 2 weitere

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-025-01206-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Chiuping Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, J…. Hauptthemen laut MEDLINE: Behcet Syndrome, Biosimilar Pharmaceuticals, Uveitis, Visual Acuity. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Behçet's Disease Research Committee, Health and Labour Sciences Research Grant, Behçet’s Disease Research Committee, Health and Labour Sciences Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study evaluated the effectiveness and safety of the biosimilar infliximab CT-P13 in treating refractory uveitis associated with Behçet's disease. STUDY DESIGN: Retrospective study. METHODS: A retrospective analysis of medical records from seven patients was conducted, categorizing them into two groups: those initially treated with CT-P13 (Group 1) and those switched from other tumor necrosis factor inhibitors (Group 2). Data on demographics, treatment duration, ocular inflammatory attacks, visual acuity changes, relapse rates, and adverse events were collected. RESULTS: Seven patients (mean age: 32.0 ± 17.7 years) with refractory uveitis associated with Behçet's disease were included. Four patients in Group 1 received CT-P13 as their first-line biologic therapy, of whom two (50%) achieved remission. All patients exhibited a significant reduction in relapses in the 6 months before and after CT-P13 treatment (Wilcoxon test, p = 0.031). Three patients in Group 2, switched from original infliximab, maintained remission for an average of 11.0 ± 2.0 months. Overall, 71.4% of patients achieved remission. No significant changes in visual acuity were observed in either group. One adverse event occurred, but no adverse drug reactions were reported. CONCLUSION: The biosimilar infliximab CT-P13 appears to be an effective and cost-efficient option for managing refractory uveitis in Behçet's disease. This finding highlights its potential in managing this challenging condition and warrants further investigation in larger patient cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeBiosimilar PharmaceuticalsUveitisVisual AcuityAntibodies, MonoclonalInfliximabHumansRetrospective StudiesMaleFemaleAdultTreatment OutcomeYoung AdultMiddle AgedFollow-Up StudiesAdolescent

Stichwörter der Autor:innen

Behçet’s diseaseBiosimilar infliximabBiosimilar therapyCT-P13Refractory uveitis

Substanzen

Biosimilar PharmaceuticalsCT-P13Antibodies, MonoclonalInfliximab

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. t226077f@yokohama-cu.ac.jp.
  • Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
  • Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Förderung

  • Behçet's Disease Research Committee, Health and Labour Sciences Research Grant
  • Behçet’s Disease Research Committee, Health and Labour Sciences Research Grant

Zitieren

APA

Lee, C., Takeuchi, M., Kawagoe, T., Nakamura, J., Shibuya, E., Ishihara, M., Yamada, N., Mizuki, Y., Meguro, A., Kirino, Y., Soejima, Y., Hirahara, L., Iizuka, Y., & Mizuki, N. (2025). Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behçet’s disease. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-025-01206-2

Vancouver

Lee C, Takeuchi M, Kawagoe T, Nakamura J, Shibuya E, Ishihara M, et al. Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behçet’s disease. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-025-01206-2

BibTeX
@article{Lee2025,
  author = {Lee, Chiuping and Takeuchi, Masaki and Kawagoe, Tatsukata and Nakamura, Jutaro and Shibuya, Etsuko and Ishihara, Mami and Yamada, Norihiro and Mizuki, Yuki and Meguro, Akira and Kirino, Yohei and Soejima, Yutaro and Hirahara, Lisa and Iizuka, Yuki and Mizuki, Nobuhisa},
  title = {Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Behçet’s disease},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-025-01206-2}
}
Kostenlos starten →